PUMA BIOTECHNOLOGY INC (PBYI) Dividend History

Company News

• Er-Kim Announces Exclusive Distribution Agreement with Puma Biotechnology to Commercialize NERLYNX® (neratinib) for Breast Cancer Patients

  Er-Kim, an international pharmaceutical company, has signed an agreement with Puma Biotechnology to commercialize NERLYNX, a targeted therapy for early-stage HER2-positive breast cancer, in select countries in Eastern Europe and Central Asia.

  GlobeNewswire Inc.
• Puma Biotechnology executive sells over $9,600 in stock - Investing.com

  Puma Biotechnology's Chief Commercial Officer, Jeffrey Jerome Ludwig, sold 2,598 shares of the company's common stock for over $9,600. The sale was part of a pre-arranged trading plan, and Ludwig's direct ownership in the company now stands at 118,388 shares.

  Investing.com
• Puma biotech exec sells shares worth over $19,000 By Investing.com - Investing.com Australia

  Puma Biotechnology's Chief Commercial Officer Jeffrey Jerome Ludwig sold 6,051 shares worth over $19,000. The sale was executed under a pre-arranged trading plan. The company has reported a decrease in total and product revenue for Q1 2024, but is actively pursuing clinical trials and refining its distribution model.

  Investing.com
• Puma Biotechnology executive sells over $14,000 in company stock By Investing.com - Investing.com Australia

  Puma Biotechnology's Senior Vice President of Regulatory Affairs, Douglas M. Hunt, sold over $14,000 worth of company stock. The sale may attract attention from investors as it comes amid recent developments, including a decline in revenue but a strong gross profit margin.

  Investing.com
• Puma Biotechnology CFO sells shares worth over $17,000 By Investing.com - Investing.com Australia

  Puma Biotechnology's CFO, Maximo F. Nougues, has sold shares worth over $17,000. The transaction was executed under a 10b5-1(c) trading plan, which allows insiders to sell shares on a predetermined schedule. The company has also been selected for inclusion in the Russell 3000 Index, which is expected to increase liquidity and exposure to institutional investors.

  Investing.com